TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22480715

Group type: EXPERIMENTAL
Intervention: PTSD Symptom Scale‐Interview (PSS‐I)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: self‐report PTSD Diagnostic Scale (PDS)
Number of subjects: 167
Study: 20053673

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - recommendations about healthy habits and adherence to treatment in group sessions for non-risk patients; individual visits by a geriatrician for at-risk patients.
Number of subjects: 620

Group type: COMPARATOR
Intervention: Control Group (CG) - usual care.
Number of subjects: 620

Group type: COMPARATOR
Intervention: Overall comparison between IG and CG.
Number of subjects: 620
Study: 18397549

Group type: EXPERIMENTAL
Intervention: Olanzapine (mean modal dose 12.0 mg/day, average duration 241 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Risperidone (mean modal dose 4.0 mg/day, average duration 86 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Olanzapine (after switch)
Number of subjects: 60
Study: 16084852

Group type: EXPERIMENTAL
Intervention: TTT haplotype (3435T, 1236T, and 2677T)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CGC haplotype (3435C, 2677G, and 1236C)
Number of subjects: 20
Study: 12437647

Group type: EXPERIMENTAL
Intervention: Eradication of Helicobacter pylori infection
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control subjects (without MGUS)
Number of subjects: 93

Group type: COMPARATOR
Intervention: H. pylori infection diagnosis rates
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: H. pylori therapy
Number of subjects: 93
Study: 10692734

Group type: EXPERIMENTAL
Intervention: Omeprazole-based triple eradication regimen (Group A, n = 39)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Omeprazole alone followed by long-term famotidine 20 mg daily (Group B, n = 34)
Number of subjects: 73
Study: 7581968

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) replacement therapy for 6 months
Number of subjects: 30
Study: 1617528

Group type: EXPERIMENTAL
Intervention: Noninvasive approach
Number of subjects: 57

Group type: COMPARATOR
Intervention: Invasive approach
Number of subjects: 57
Study: 6712754

Group type: EXPERIMENTAL
Intervention: Oral pulse methotrexate therapy (2.5-5.0 mg every 12 hours in 3 consecutive doses per week)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Oral pulse methotrexate therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 31037566

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Fibrin glue
Number of subjects: 56
Study: 29864374

Group type: EXPERIMENTAL
Intervention: Mechanical impact simulator
Number of subjects: 45
Study: 26421810

Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg orally 2 hours before surgery and 24 hours after surgery)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 70
Study: 24333007

Group type: EXPERIMENTAL
Intervention: Nicotinic acid/Laropiprant 1g/20mg for 4 weeks followed by 2g/40mg for 6 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Nicotinic acid/Laropiprant
Number of subjects: 82
Study: 22322110

Group type: EXPERIMENTAL
Intervention: +6D high water content daily disposable lens
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: -6D high water content daily disposable lens
Number of subjects: 39
Study: 19948382

Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone dosing condition (19.7 mg for extreme pain, 15.0 mg for some pain, 12.8 mg for no pain)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone dosing condition
Number of subjects: 69
Study: 18426421

Group type: EXPERIMENTAL
Intervention: +0.75 D lens addition
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: +1.50 D lens addition
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: +2.25 D lens addition
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: +3.00 D lens addition
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 6-Delta base-in prism with +1.50 D lens addition
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: +2.25 D lens addition with 6-Delta base-in prism
Number of subjects: 29
Study: 15951075

Group type: EXPERIMENTAL
Intervention: Hand Elevation test
Number of subjects: 48

Group type: COMPARATOR
Intervention: Tinel's test
Number of subjects: 48

Group type: COMPARATOR
Intervention: Phalen's test
Number of subjects: 48
Study: 14703266

Group type: EXPERIMENTAL
Intervention: Drop-in center program that eliminated barriers to access to services
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Apartment program with subsidized apartments and services under participants' control
Number of subjects: 393

Group type: COMPARATOR
Intervention: Control group (usual continuum of care)
Number of subjects: 393
Study: 10388426

Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron 0.15 mg/kg with induction of anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo of normal saline 0.3 ml/kg with induction of anesthesia
Number of subjects: 0
Study: 8710717

Group type: EXPERIMENTAL
Intervention: Alum-containing mouthrinse (0.02 M alum), rinsed once daily for 30 seconds
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 48
Study: 1948121

Group type: EXPERIMENTAL
Intervention: Leuprolide plus flutamide
Number of subjects: 603

Group type: COMPARATOR
Intervention: Leuprolide plus placebo
Number of subjects: 603
Study: 6841506

Group type: EXPERIMENTAL
Intervention: Methylphenidate (mean daily dose 44.2 mg/day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Methylphenidate and reading instruction
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo and reading instruction
Number of subjects: 66
Study: 31940698

Group type: EXPERIMENTAL
Intervention: Erythropoietin (1000 U/kg every 48 hours for six doses, then 400 U/kg three times per week until 32 weeks postmenstrual age)
Number of subjects: 941

Group type: COMPARATOR
Intervention: Placebo (intravenous saline and sham injections)
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 941

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 941
Study: 31607143

Group type: EXPERIMENTAL
Intervention: Intensive treatment (24-hour mean systolic BP ≤130 mm Hg)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Standard treatment (24-hour mean systolic BP ≤145 mm Hg)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 199

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 199
Study: 27930500

Group type: EXPERIMENTAL
Intervention: Rivastigmine (up to 6 mg/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: COMPARATOR
Intervention: Prior treatment regimen (SSRIs plus sodium valproate)
Number of subjects: 36
Study: 25911899

Group type: EXPERIMENTAL
Intervention: rebamipide 300 mg daily for 8 weeks plus rabeprazole 20 mg daily for the first 4 weeks (reb+PPI group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: rabeprazole 20 mg daily for 8 weeks (PPI group)
Number of subjects: 0
Study: 24703195

Group type: EXPERIMENTAL
Intervention: Mirabegron 25 mg qd
Number of subjects: 2736

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg qd
Number of subjects: 2736

Group type: EXPERIMENTAL
Intervention: Mirabegron 100 mg qd
Number of subjects: 2736

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2736

Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg
Number of subjects: 2736
Study: 25191556

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ) 500 ml
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo drink 500 ml
Number of subjects: 28
Study: 18972429

Group type: EXPERIMENTAL
Intervention: Intra-arterial (IA) chemoradiation
Number of subjects: 207

Group type: COMPARATOR
Intervention: Intravenous (IV) chemoradiation
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Both IA and IV groups
Number of subjects: 207
Study: 17892539

Group type: EXPERIMENTAL
Intervention: Laterally wedged insoles
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control flat insoles
Number of subjects: 200
Study: 15976208

Group type: EXPERIMENTAL
Intervention: bupivacaine-neostigmine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: bupivacaine-midazolam
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: bupivacaine-ketamine
Number of subjects: 80

Group type: COMPARATOR
Intervention: bupivacaine alone
Number of subjects: 80
Study: 12069211

Group type: COMPARATOR
Intervention: Steady-state group (24 outpatients)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: VOC group (14 inpatients during crisis)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Steady-state and VOC groups
Number of subjects: 47
Study: 9489264

Group type: EXPERIMENTAL
Intervention: Task Force's selection of criteria for identifying effective treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Less stringent and controlled research designs
Number of subjects: 0
Study: 7616875

Group type: EXPERIMENTAL
Intervention: Oral administration of progesterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vaginal administration of progesterone
Number of subjects: 0
Study: 1754870

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 0
Study: 6820344

Group type: EXPERIMENTAL
Intervention: Verapamil (360 mg/die)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg/die)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 31819995

Group type: EXPERIMENTAL
Intervention: Abatacept plus MTX
Number of subjects: 881

Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 881
Study: 30900392

Group type: EXPERIMENTAL
Intervention: Fosaprepitant 3.0 mg/kg (up to 150 mg)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Fosaprepitant 1.2 mg/kg (up to 60 mg)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Fosaprepitant 0.4 mg/kg (up to 20 mg)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Fosaprepitant 5.0 mg/kg (up to 150 mg) in subjects under 12 years
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 29453466

Group type: EXPERIMENTAL
Intervention: Intrathecal Dexmedetomidine (5 micrograms)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Hyperbaric Bupivacaine 0.5% (2.5 ml)
Number of subjects: 76
Study: 27553824

Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT)
Number of subjects: 0
Study: 24046462

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Non-rebreathing mask
Number of subjects: 17
Study: 22490626

Group type: EXPERIMENTAL
Intervention: Valsartan + Amlodipine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Valsartan + Hydrochlorothiazide
Number of subjects: 61
Study: 20073301

Group type: EXPERIMENTAL
Intervention: Conventional discectomy (group A, 25 cases)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Posterior lumbar interbody fusion (PLIF) (group B, 22 cases)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Transforaminal lumbar interbody fusion (TLIF) (group C, 18 cases)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Posterior lumbar interbody fusion (PLIF) (group B)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Conventional discectomy (group A)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Transforaminal lumbar interbody fusion (TLIF) (group C)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intervertebral space height (ISH)
Number of subjects: 65
Study: 17233426

Group type: EXPERIMENTAL
Intervention: Benzodiazepines (shorter-acting) for adjustment disorder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antidepressants for major depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuroleptics (haloperidol) for delirium
Number of subjects: 0
Study: 15037867

Group type: EXPERIMENTAL
Intervention: His452Tyr genotype
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fenfluramine response
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: T102C genotype
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 12577248

Group type: EXPERIMENTAL
Intervention: Subcutaneous amifostine 500 mg before each radiation therapy fraction
Number of subjects: 41

Group type: COMPARATOR
Intervention: No amifostine (control group)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Subcutaneous amifostine
Number of subjects: 41
Study: 9881038

Group type: EXPERIMENTAL
Intervention: Screening programs for early diagnosis of colorectal cancer
Number of subjects: 0
Study: 8567765

Group type: EXPERIMENTAL
Intervention: Recombinant FSH (Puregon)
Number of subjects: 981

Group type: COMPARATOR
Intervention: Urinary FSH (Metrodin)
Number of subjects: 981
Study: 2665492

Group type: EXPERIMENTAL
Intervention: 365 mg of elemental magnesium daily (as magnesium aspartate hydrochloride)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 374
Study: 343024

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with adriamycin
Number of subjects: 117

Group type: COMPARATOR
Intervention: Combination chemotherapy without adriamycin
Number of subjects: 117
Study: 31653260

Group type: EXPERIMENTAL
Intervention: Intervention group (attended twice weekly exercise and nutrition classes for 24 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention group (self-reported physical activity)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (attended didactic healthy lifestyle classes monthly)
Number of subjects: 0
Study: 28575761

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 800mg QD
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1200mg QD
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 400mg QD
Number of subjects: 1447

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1447
Study: 26466310

Group type: EXPERIMENTAL
Intervention: Comorbid PTSD and major depressive disorder (MDD)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: PTSD numbing symptoms
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 158

Group type: COMPARATOR
Intervention: PTSD alone
Number of subjects: 158
Study: 22543515

Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 30
Study: 21131392

Group type: EXPERIMENTAL
Intervention: Pilot drilling with a diameter of 1.1 mm (Group I)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Pilot drilling with a diameter of 0.9 mm (Group II)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Drill-free method (Group III)
Number of subjects: 62
Study: 19715461

Group type: EXPERIMENTAL
Intervention: Patients in hospital rooms with live plants during postoperative recovery periods
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (patients in similar rooms without plants)
Number of subjects: 90
Study: 17916223

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum + motivational interviewing counseling
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum + Health Education counseling
Number of subjects: 755

Group type: COMPARATOR
Intervention: Placebo + motivational interviewing counseling
Number of subjects: 755

Group type: COMPARATOR
Intervention: Placebo + Health Education counseling
Number of subjects: 755
Study: 15289215

Group type: EXPERIMENTAL
Intervention: Early invasive strategy (medical therapy and coronary angiography at 4 to 48 hours)
Number of subjects: 2220

Group type: COMPARATOR
Intervention: Conservative strategy (medical therapy and predischarge exercise testing)
Number of subjects: 2220

Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 2220
Study: 11450767

Group type: EXPERIMENTAL
Intervention: Limited macular translocation (LMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Photodynamic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study: 9371851

Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) measuring brain activity in dyslexic subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Functional magnetic resonance imaging (fMRI) measuring brain activity in control subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation analysis of reading rate and brain activity
Number of subjects: 0
Study: 7951640

Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 0
Study: 3310628

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g suspension four times daily for eight weeks)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Ranitidine (150 mg film-coated tablet twice daily for eight weeks)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 49

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 49
Study: 28645542

Group type: EXPERIMENTAL
Intervention: Inclusion of ingroup member who challenged the group's norm in moral contexts
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Inclusion of outgroup member who supported the group's norm in social-conventional contexts
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Age-related differences in inclusion decisions
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Reasoning about inclusion decisions
Number of subjects: 73
Study: 26280662

Group type: EXPERIMENTAL
Intervention: Antioxidant-essential oil gel applied twice daily after brushing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (placebo gel)
Number of subjects: 30
Study: 24962527

Group type: EXPERIMENTAL
Intervention: Syndesmotic screw fixation
Number of subjects: 140

Group type: COMPARATOR
Intervention: No syndesmotic fixation
Number of subjects: 140
Study: 23498303

Group type: EXPERIMENTAL
Intervention: Lifestyle weight-loss intervention (7% weight loss goal achieved and maintained by caloric restriction and increased physical activity)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Usual care (two visits with a registered dietitian and monthly newsletters)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Lifestyle weight-loss intervention
Number of subjects: 301
Study: 21624216

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 63
Study: 18165968

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17056953

Group type: EXPERIMENTAL
Intervention: BIS-guided sedation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: AAI-guided sedation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: BIS/AAI-guided sedation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clinically guided sedation
Number of subjects: 100
Study: 14583134

Group type: EXPERIMENTAL
Intervention: 0.5% timolol/2.0% MK-507 combination b.i.d.
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.5% timolol b.i.d. and 2.0% MK-507 b.i.d. (concomitant treatment)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 20
Study: 10760103

Group type: EXPERIMENTAL
Intervention: SB 290670 (mixed endothelin A and B receptor antagonist)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: SB 290670
Number of subjects: 158
Study: 8813984

Group type: EXPERIMENTAL
Intervention: Clindamycin (1200 mg) via TVA-Bier
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Gentamicin (284 mg) via TVA-Bier
Number of subjects: 32

Group type: COMPARATOR
Intervention: Clindamycin (1200 mg) via intravenous/intra-arterial injection
Number of subjects: 32

Group type: COMPARATOR
Intervention: Gentamicin (284 mg) via intravenous/intra-arterial injection
Number of subjects: 32
Study: 1445966

Group type: EXPERIMENTAL
Intervention: Clonidine 0.25 micrograms/kg IV
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Clonidine 0.5 micrograms/kg IV
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Clonidine 1 microgram/kg IV
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms/kg IV
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 4015079

Group type: EXPERIMENTAL
Intervention: Intranasal HuIFN‐alpha 2 (1.25 X 10(6) IU)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study: 30765294

Group type: EXPERIMENTAL
Intervention: Fragility Index (FI)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Fragility Index (FI) in ischemic stroke RCTs
Number of subjects: 206
Study: 29630755

Group type: EXPERIMENTAL
Intervention: FraGW (automated breast density measure)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fra80 (previous breast density measurement)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MRD (converted from FraGW)
Number of subjects: 50
Study: 26658173

Group type: EXPERIMENTAL
Intervention: Cortisol (hydrocortisone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 0
Study: 24182419

Group type: EXPERIMENTAL
Intervention: Sumatriptan (50 mg) plus promethazine (25 mg)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Sumatriptan (50 mg) plus placebo
Number of subjects: 242
Study: 22825231

Group type: EXPERIMENTAL
Intervention: Multimodal intervention (training to implement AAR, workflow integration recommendations, tobacco cessation poster, support visit)
Number of subjects: 16
Study: 20414672

Group type: EXPERIMENTAL
Intervention: Random forced oscillation pressure wave on spontaneous respiration
Number of subjects: 10
Study: 18584220

Group type: EXPERIMENTAL
Intervention: 2% or 3% N-chlorotaurine (NCT) mouth rinse
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: N-chlorotaurine (NCT) mouth rinse
Number of subjects: 80

Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 80

Group type: COMPARATOR
Intervention: Positive control
Number of subjects: 80